Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical Group's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.39.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.85.
During the past 12 months, the average EBIT per Share Growth Rate of Simcere Pharmaceutical Group was 33.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 38.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 30.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Simcere Pharmaceutical Group's EBIT per Share or its related term are showing as below:
HKSE:02096'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.7 Med: -1.25 Max: 71.4
Current: 38.7
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Simcere Pharmaceutical Group was 71.40% per year. The lowest was -36.70% per year. And the median was -1.25% per year.
HKSE:02096's 3-Year EBIT Growth Rate is ranked better than 83.35% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs HKSE:02096: 38.70
Simcere Pharmaceutical Group (HKSE:02096) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Simcere Pharmaceutical Group EBIT per Share Related Terms
Simcere Pharmaceutical Group EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (HKSE:02096) has a EBIT per Share of HK$0.85 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Simcere Pharmaceutical Group and its competitors. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #135 out of 811 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Simcere Pharmaceutical Group's EBIT per Share too high?
Simcere Pharmaceutical Group's current EBIT per Share is HK$0.85. Based on the distribution chart, Simcere Pharmaceutical Group ranks #135 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Simcere Pharmaceutical Group has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #135 out of 811 companies for EBIT per Share. This places Simcere Pharmaceutical Group in the top 17% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current EBIT per Share is HK$0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (HKSE:02096) is currently considered Fairly Valued. The stock's GF Value™ is HK$11.18, compared to a current price of HK$10.96 — trading 2% below its estimated fair value. The current EBIT per Share is HK$0.85. Simcere Pharmaceutical Group's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Simcere Pharmaceutical Group (HKSE:02096), the current EBIT per Share is HK$0.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (HKSE:02096) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be undervalued.
The current stock price of HK$10.96 is trading 2% below its estimated GF Value™ of HK$11.18.
GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.
Key valuation signals for HKSE:02096:
EBIT per Share: HK$0.85
GF Value™: HK$11.18 vs. price of HK$10.96 (2% below fair value)
No single metric tells the full story. See the HKSE:02096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
95GF Score
Get the complete analysis for HKSE:02096
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02096 has been successfully added to your 
